Cellectar Biosciences shares surge 14.89% premarket after securing key patents for iopofosine I 131 ahead of EMA filing.

Cellectar Biosciences (NASDAQ: CLRB) surged 14.89% in premarket trading following the announcement of expanded global intellectual property (IP) protection for its cancer-targeting drug candidates. The company secured new patents across Europe, Asia-Pacific, the Middle East, and the Americas, covering iopofosine I 131 (a radiotherapeutic for Waldenström macroglobulinemia) and CLR-125 (an Auger-emitting radiopharmaceutical for triple-negative breast cancer). These patents strengthen IP coverage ahead of a planned 3Q26 conditional marketing authorization filing with the European Medicines Agency (EMA) for iopofosine I 131. The CEO emphasized the strategic importance of these patents in fortifying the company’s portfolio and supporting long-term commercial goals. The news reinforced investor confidence in Cellectar’s pipeline advancements and regulatory progress, directly aligning with the stock’s premarket gains.